Adoption of Evidence-based clinical innovations: The case of buprenorphine use by opioid treatment programs

Medical Care Research and Review

Volumn 71, Issue 1, 2014, Pages 43-60

  Andrews, Christina M ^a   D'Aunno, Thomas A ^b   Pollack, Harold A ^c   Friedmann, Peter D ^d  

^a UNIVERSITY OF SOUTH CAROLINA   (United States)

^b Och Spine at New York Presbyterian Hospitals   (United States)

^c UNIVERSITY OF CHICAGO   (United States)

^d RHODE ISLAND HOSPITAL   (United States)

Author keywords

adoption; buprenorphine; evidence based practice; innovation; opioid treatment

Indexed keywords

BUPRENORPHINE; METHADONE; NARCOTIC ANTAGONIST;

ARTICLE; COMPETITION; CONCEPTUAL FRAMEWORK; DETOXIFICATION; DRUG COST; DRUG MARKETING; EVIDENCE BASED PRACTICE; HEALTH CARE PERSONNEL; HEALTH CARE POLICY; HEALTH PROGRAM; HEALTH SERVICE; HUMAN; INSURANCE; MAINTENANCE THERAPY; SOCIAL SUPPORT; DRUG DEPENDENCE TREATMENT; EVIDENCE BASED MEDICINE; MASS COMMUNICATION; OPIATE SUBSTITUTION TREATMENT; OPIOID-RELATED DISORDERS; PROCEDURES; UTILIZATION;

BUPRENORPHINE; DIFFUSION OF INNOVATION; EVIDENCE-BASED MEDICINE; HUMANS; NARCOTIC ANTAGONISTS; OPIATE SUBSTITUTION TREATMENT; OPIOID-RELATED DISORDERS; SUBSTANCE ABUSE TREATMENT CENTERS;

EID: 84891866629     PISSN: 10775587     EISSN: 15526801     Source Type: Journal    
DOI: 10.1177/1077558713503188     Document Type: Article

References (38)

1. D'Aunno T., Foltz-Murphy N., Lin X. Changes in methadone treatment practices: Results from a panel study: 1988-1995. American Journal of Drug and Alcohol Abuse. 1999 ; 25: 681-699
2. D'Aunno T., Pollack H. A. Changes in methadone treatment practices: Results from a national panel study, 1988-2000. Journal of the American Medical Association. 2002 ; 288: 850-856
3. D'Aunno T., Vaughn T. E. Variations in methadone treatment practices: Results from a national study. Journal of the American Medical Association. 1992 ; 267: 253-258
4. Damschroder L., Aron D., Keith R., Kirsh S., Alexander J., Lowery J. Fostering implementation of health services research findings into practice: A consolidated framework for advancing implementation science. Implementation Science. 2009 ; 4: 50
5. Diggle P. J., Liang K. Y., Zeger S. L. Analysis of longitudinal data. Oxford, England: Oxford University Press ; 1994 :
6. Ducharme L. J., Abraham A. J. State policy influence on the early diffusion of buprenorphine in community treatment programs. Substance Abuse Treatment, Prevention, and Policy. 2008 ; 3 (1). 17
7. Ducharme L. J., Knudsen H. K., Roman P. M., Johnson J. A. Innovation adoption in substance abuse treatment: Exposure, trialability, and the clinical trials network. Journal of Substance Abuse Treatment. 2007 ; 32: 321-329
8. Ducharme L. J., Roman P. M. Opioid treatment programs in the Clinical Trials Network: Representativeness and buprenorphine adoption. Journal of Substance Abuse Treatment. 2009 ; 37: 90-94
9. Eccles M. P., Mittman B. S. Welcome to implementation science. Implementation Science. 2006 ; 1 (1). 1
10. Feldstein A. C., Glasgow R. E. A practical, robust implementation and sustainability model (PRISM). Joint Commission Journal on Quality and Patient Safety. 2008 ; 34: 228-243
11. Fixsen D. L., Naoom S. F., Blase K. A., Friedman R. M., Wallace F. Implementation research: A synthesis of the literature. Tampa: University of South Florida, Louis de la Parte Florida Mental Health Institute, The National Implementation Research Network ; 2005 :
12. Friedmann P. D., Jiang L., Alexander J. A. Top manager effects on buprenorphine adoption in outpatient substance abuse treatment programs. Journal of Behavioral Health Services and Research. 2010 ; 37: 322-336
13. Groves R. M. Theories and methods of telephone surveys. Annual Review of Sociology. 1990 ; 16: 221-240
14. Crossing the quality chasm in mental and substance use treatment. Washington, DC: National Academies Press ; 2005 :
15. Kleber H. D. Pharmacologic treatments for opioid dependence: Detoxification and maintenance options. Dialogues in Clinical Neuroscience. 2007 ; 9: 455-470
16. Knudsen H. K., Abraham A. J. Perceptions of the state policy environment and adoption of medications in the treatment of substance use disorders. Psychiatric Services. 2012 ; 63 (1). 19-25
17. Knudsen H. K., Abraham A. J., Johnson J. A., Roman P. M. Buprenorphine adoption in the National Drug Abuse Treatment Clinical Trials Network. Journal of Substance Abuse Treatment. 2009 ; 37: 307-312
18. Knudsen H. K., Abraham A. J., Oser C. B. Barriers to the implementation of medication-assisted treatment for substance use disorders: The importance of funding policies and medical infrastructure. Evaluation and Program Planning. 2011 ; 34: 375-381
19. Knudsen H. K., Abraham A. J., Roman P. M. Adoption and implementation of medications in addiction treatment programs. Journal of Addiction Medicine. 2011 ; 5 (1). 21-27
20. Knudsen H. K., Ducharme L. J., Roman P. M. Early buprenorphine adoption in substance abuse treatment centers: Data from the private and public sectors. Journal of Substance Abuse Treatment. 2006 ; 30: 363-373
21. Knudsen H. K., Roman P. M., Oser C. B. Facilitating factors and barriers to the use of medications in publicly funded addiction treatment organizations. Journal of Addiction Medicine. 2010 ; 4 (2). 99-107
22. Koch A. L., Arfken C. L., Schuster C. R. Characteristics of U.S. substance abuse treatment facilities adopting buprenorphine in its initial stage of availability. Drug and Alcohol Dependence. 2006 ; 83: 274-278
23. Lamb S. J., Greenlick M. R., McCarty D. Bridging the gap between practice and research: Forging partnerships with community-based drug and alcohol treatment. Washington, DC: National Academies Press ; 1998 :
24. Little R. A., Rubin D. B. Statistical analysis with missing data. New York, NY: Wiley-Interscience ; 2002 :
25. Mattick R. P., Kimber J., Breen C., Davoli M. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Oxford, England: Cochrane Collaboration ; 2008 :
26. Pollack H. A., D'Aunno T. Dosage patterns in methadone treatment: Results from a national survey, 1988-2005. Health Services Research. 2008 ; 43: 2143-2163
27. Pollack H. A., D'Aunno T. HIV testing and counseling in the nation's outpatient substance abuse treatment system, 1995-2005. Journal of Substance Abuse Treatment. 2010 ; 38: 307-316
28. Reif S., Thomas C. P., Wallack S. S. Factors determining how early adopter physicians use buprenorphine in treatment. Journal of Addiction Medicine. 2007 ; 1: 205-212
29. Roman P. M., Abraham A. J., Knudsen H. K. Using medication-assisted treatment for substance use disorders: Evidence of barriers and facilitators of implementation. Addictive Behaviors. 2011 ; 36: 584-589
30. Rubin D. B. Multiple imputation for nonresponse in surveys. New York, NY: Wiley ; 1987 :
31. Rye C. B., Kimberly J. R. The adoption of innovations by provider organizations in health care. Medical Care Research and Review. 2007 ; 64: 235-278
32. Schaefer J. L. Analysis of incomplete multivariate data. New York, NY: Chapman & Hall ; 1997 :
33. Stein M. D., Friedmann P. D. Optimizing opioid detoxification: Rearranging deck chairs on the Titanic. Journal of Addictive Diseases. 2007 ; 26 (2). 1-2
34. Stein B. D., Gordon A. J., Sorbero M., Dick A. W., Schuster J., Farmer C. The impact of buprenorphine on treatment of opioid dependence in a Medicaid population: Recent service utilization trends in the buprenorphine use and methadone. Drug and Alcohol Dependence. 2011 ; 123: 72-78
35. Wallack S. S., Thomas C. P., Martin T. C., Chilingerian J., Reif S. Substance abuse treatment organizations as mediators of social policy: Slowing the adoption of a congressionally approved medication. Journal of Behavioral Health Services and Research. 2010 ; 37 (1). 64-78
36. Wooldridge J. M. Econometric analysis of cross section and panel data. Cambridge: MIT Press ; 2002 :
37. Woolf S. H. The meaning of translational research and why it matters. Journal of the American Medical Association. 2008 ; 299: 211-213
38. Zerhouni E. The NIH roadmap. Science. 2003 ; 302: 63-72